ArticleBMC infectious diseases2023
Evaluation of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: Epidemiology, clinical characteristics, and outcomes in the older patients in a tertiary teaching hospital in Malaysia.
Article in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Changes in antimicrobial resistance of staphylococci isolated from bloodstream infection and the impact of COVID-19.BMC infectious diseases · 2026Article
- Methicillin-resistant Staphylococcus aureus bloodstream infections in the Northern Territory of Australia 2017-2022.Internal medicine journal · 2026Observational
- Impact of Methicillin Resistance on Outcomes ofOpen forum infectious diseases · 2026Article
- Plasmid diversity, antibiotic resistance and virulence genes associated with Staphylococcus aureus isolates from private hospitals in Gauteng, South Africa.World journal of microbiology & biotechnology · 2026Article
- Development and validation of a prognostic model incorporating the blood urea nitrogen-to-albumin ratio for predicting mortality in methicillin-resistant Staphylococcus aureus bloodstream infection.BMC infectious diseases · 2026Article
- Distinct genetic programs drive antibiotic resistance and intracellular invasion in emerging MRSA strains.mSystems · 2026Article
- Virulence-Selective Trap-Capture-Kill Antibacterial Nanostructures With Immune-Metabolic Regulation for Treating Implant-Associated Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Unveiling the spectrum of vancomycin resistance in Staphylococcus aureus from Hospital-acquired urinary tract infections (HA-UTI) in cardiac patients.Molecular biology reports · 2025Article
- Prevalence of methicillin-resistantIJID regions · 2025Article
- Methicillin-resistant Staphylococcus aureus (MRSA) infection of the temple region of the face: Case report.Medicine · 2025Article
- Exploring catalase inhibition as an adjuvant to antimicrobial photodynamic therapy against Staphylococcus aureus.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2025Article
- Prevalence, Antibiotic Susceptibility Pattern and the Detection ofIndian journal of microbiology · 2025Article
- MRSA Profiles Reveal Age- and Gender-Specificity in a Tertiary Care Hospital: High Burden in ICU Elderly and Emerging Community Patterns in Youth.Microorganisms · 2025Article
- Article
- Methicillin-resistantCurrent pharmaceutical biotechnology · 2025Review
- Risk Factors for Methicillin-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Article
- The Prevalence, Epidemiological, and Molecular Characterization of Methicillin-ResistantMicroorganisms · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
backgroundMethicillin-resistant Staphylococcus aureus (MRSA) bacteremia is a major concern in the global healthcare system. However, data from Asian regions dealing with the singularity of this infection in older persons is lacking. We aimed to identify the differences in the clinical characteristics and outcomes of MRSA bacteremia between adults aged 18-64 and ≥ 65 years.
methodsA retrospective study cohort was conducted at the University Malaya Medical Centre (UMMC) on cases of MRSA bacteremia from 2012 to 2016. Patient demographic and clinical data were collected for risk factors analyses.
resultsNew cases of MRSA bacteremia showed a trend of increase from 0.12 to 100 admissions in 2012 to 0.17 per 100 admissions in 2016 but a drop was observed in 2014 (0.07 per 100 admissions). Out of the 275 patients with MRSA bacteremia, 139 (50.5%) patients were aged ≥ 65 years old. Co-morbidities and severity at presentation were significantly higher among older adults, including diabetes mellitus (p = 0.035), hypertension (p = 0.001), and ischemic heart disease (p < 0.001), as well as higher Charlson Comorbidity Index (p < 0.001) and Pitt bacteremia scores (p = 0.016). Central line-associated bloodstream infections were more common among younger patients (37.5% vs. 17.3% in older patients, p < 0.001), while skin and soft tissue infections are more frequent among older adults (20.9% vs. 10.3% in younger patients, p = 0.016). All-cause mortality and in-hospital mortality were significantly higher in older patients (82.7% and 56.1% vs. 63.2% and 28.7% in younger patients, p < 0.001). Multivariate analysis revealed age ≥ 65 years (adjusted odds ratio: 3.36; 95% confidence interval: 1.24-9.13), Pitt score ≥ 3 (2.15; 1.54-3.01), hospital (6.12; 1.81-20.72) and healthcare (3.19; 1.30-7.81) acquisition of MRSA, indwelling urinary catheters (5.43; 1.39-21.23), inappropriate targeted treatment (8.08; 1.15-56.86), lack of infectious disease team consultation (2.90; 1.04-8.11) and hypoalbuminemia (3.31; 1.25-8.79), were significant risk factors for 30-day mortality.
conclusionOlder patients' risk of mortality from MRSA bacteremia was three times higher than younger patients. Our data will contribute to developing and validating a robust scoring system for risk-stratifying patients to achieve better management and improved clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.